Pricing Log in Create free account
Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.63 1.00 +1.40%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Corcept Therapeutics Incorporated 10-Q filed Jul 29, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:09 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Apr 30, 2026: 5 added · 3 removed · 43 modified; 2 with only figures updated